Newspaper Advertisement regarding publication of unaudited financial result of the company for the quarter ended 30 June, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Genomic Valley Biotech Ltd has published its unaudited Q1 FY26 results in Financial Express (English) and Jansatta (Hindi) as required under SEBI listing rules. Total income from operations stood at Rs. 9.00 lakhs, down sharply from Rs. 15.53 lakhs in the same quarter last year (a ~42% YoY drop). Net profit after tax came in at Rs. 2.47 lakhs, compared to Rs. 12.76 lakhs in Q1 FY25 — an ~81% YoY decline. EPS for the quarter was Rs. 0.08 versus Rs. 0.42 in the year-ago quarter. The results were reviewed by the Audit Committee and approved by the Board on 7 August 2025. Equity share capital remained unchanged at Rs. 3.05 crore (face value Rs. 10).
Sharp year-on-year decline in both revenue and profit signals a significant slowdown in the company's business this quarter, which may concern shareholders given the already small scale of operations. The figures are unaudited and the full result format is available on BSE and the company's website for closer review.